The February special issue of SLAS Discovery, ‘Advances in Cellular Target Engagement and Target Deconvolution,’ features 11 articles focused on multiple aspects and technologies of cellular target engagement.
February 2021
The February special issue of SLAS Discovery, ‘Advances in Cellular Target Engagement and Target Deconvolution,’ features 11 articles focused on multiple aspects and technologies of cellular target engagement.
The issue also features an article titled ‘The Opportunities and Use of Imaging to Ensure Target Engagement’ authored by Dr Juliana Maynard and Dr Philippa Hart, Lead Scientists at Medicines Discovery Catapult.
Proof of target engagement is a crucial element of drug discovery. While biochemical analysis of drug-target engagement is routinely deployed in projects, the ability to directly measure target engagement in cells and tissues, providing the critical link between drug-target binding and phenotype, is still in its relative infancy. As highlighted in this issue of SLAS Discovery, methods are emerging that allow for measuring cellular target engagement in a high-throughput and miniaturized manner, amenable for application in drug discovery projects. When applied in combination, these methods can build a strong platform of evidence linking compound to target to biological response, thereby impacting project attrition and medicine discovery success.
February’s SLAS Discovery includes the following reviews and perspectives:
Access to this special issue of SLAS Discovery is available here.
More information on MDC’s Pre-clinical Imaging expertise is available here.
PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.